GAITHERSBURG, Md. - Novavax , Inc. (NASDAQ:NVAX), a biotechnology company specializing in protein-based vaccines, today announced the appointment of Ruxandra Draghia-Akli, MD, PhD, as its new Executive Vice President and Head of Research & Development (R&D), effective November 2024. Dr. Draghia-Akli, with over two decades of experience in clinical, corporate, and global public health, will play a pivotal role in guiding Novavax's strategic R&D endeavors as the company focuses on expanding its vaccine technology platform and partnerships.
With a history of leadership positions in both large pharmaceutical firms and biotech startups, Dr. Draghia-Akli most recently spearheaded global public health R&D initiatives at Johnson & Johnson. Her efforts encompassed accelerating drug discovery and development for diseases such as Dengue, tuberculosis, leprosy, and coronaviruses. Prior to that, she contributed to the advancement of vaccines against Ebola, pneumococcal disease, and human papilloma virus at Merck. Her career also includes significant contributions to research and innovation policy at the European Commission, as well as securing funding and grants for early-stage research.
John C. Jacobs, President and CEO of Novavax, expressed confidence in Dr. Draghia-Akli's ability to lead the company's R&D strategy during this critical phase. Novavax is known for its COVID-19 vaccine and is developing a pipeline that includes combination vaccines for COVID-19 and influenza, as well as standalone influenza vaccine candidates. The company's technology also features in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine.
Dr. Draghia-Akli's predecessor, Filip Dubovsky, MD MPH, retired in July 2024 but continues as an Executive Advisor. Robert Walker, MD, remains the Chief Medical Officer of Novavax after serving as interim Head of R&D.
Statements in the press release regarding Novavax's future R&D plans and the potential of its clinical pipeline constitute forward-looking statements, which are subject to various risks and uncertainties that could cause actual results to differ materially from those projected.
This news report is based on a press release statement from Novavax, Inc.
In other recent news, Novavax, Inc. has rolled out an updated COVID-19 vaccine across U.S. pharmacies. Targeting the JN.1 variant, the vaccine has secured Emergency Use Authorization from the U.S. Food and Drug Administration for individuals aged 12 and older. Novavax's Q2 2024 revenue reached $415 million, largely attributed to a significant partnership with Sanofi (NASDAQ:SNY). The company plans to reduce costs and implement a more efficient R&D model for 2025, while preparing for the upcoming U.S. vaccination season with plans to launch its updated COVID-19 vaccine in select European markets. Furthermore, Novavax is renegotiating or exiting Advance Purchase Agreements for vaccine distribution and exploring the sale of its Czech Republic manufacturing facility to further reduce operating costs. The company anticipates total revenue of between $700 million and $800 million for the full year 2024, with the majority of product sales expected in Q4. These recent developments point to Novavax's strategic focus on cost reduction, efficiency, and innovative partnerships.
InvestingPro Insights
As Novavax, Inc. (NASDAQ:NVAX) welcomes Dr. Ruxandra Draghia-Akli to spearhead its R&D efforts, the company's financial health and market performance are key factors for investors to consider. According to InvestingPro data, Novavax holds a market capitalization of approximately $2.13 billion. Despite the challenges faced by the biotech industry, Novavax has managed to maintain a strong cash position, holding more cash than debt on its balance sheet, an InvestingPro Tip that underscores the company's financial resilience.
Investors should note that Novavax's revenue for the last twelve months as of Q2 2024 stands at $987.67 million, reflecting a significant decrease of 38.17%. This aligns with analysts' expectations of a sales decline in the current year, another InvestingPro Tip that may impact the company's future performance. Moreover, Novavax has experienced a substantial price uptick over the last six months, with a 176.3% return, showcasing a remarkable recovery in investor confidence.
While Novavax has demonstrated a high return over the last year, with an 81.81% price total return, analysts do not anticipate the company will be profitable this year, and it does not pay a dividend to shareholders. These InvestingPro Tips highlight the importance of strategic R&D investments and the potential for Dr. Draghia-Akli's leadership to catalyze future growth and profitability.
For investors seeking a deeper dive into Novavax's performance metrics and strategic insights, InvestingPro offers additional tips and data analysis. To access this comprehensive resource, visit https://www.investing.com/pro/NVAX.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.